>Treated as drugs, not devices? Perhaps this is because the device is easily removable?<
There’s not much logic here on the FDA’s part; for instance, Restylane from MRX is regulated as a device even though the only device that’s part of a Restylane treatment is the syringe used to inject it.
>I hope this would accelerate the review process.<
The point Barclay was trying to make on the CC was that MRK already has a good working relationship with the DAIOP group at the FDA and this will presumably help in mapping out the clinical program for I-vation.